268 related articles for article (PubMed ID: 15606328)
1. Ibandronate: its pharmacology and clinical efficacy in the management of tumor-induced hypercalcemia and metastatic bone disease.
Heidenreich A; Ohlmann CH
Expert Rev Anticancer Ther; 2004 Dec; 4(6):991-1005. PubMed ID: 15606328
[TBL] [Abstract][Full Text] [Related]
2. Ibandronate, an experimental intravenous bisphosphonate for osteoporosis, bone metastases, and hypercalcemia of malignancy.
Guay DR
Pharmacotherapy; 2006 May; 26(5):655-73. PubMed ID: 16637795
[TBL] [Abstract][Full Text] [Related]
3. [Bone targeting agents: bisphosphonates].
Debiais F
Bull Cancer; 2013 Nov; 100(11):1199-206. PubMed ID: 24158668
[TBL] [Abstract][Full Text] [Related]
4. Bisphosphonates for cancer patients: why, how, and when?
Body JJ; Mancini I
Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
[TBL] [Abstract][Full Text] [Related]
5. [Biphosphonates in oncology].
Khosravi Shahi P; Díaz Muñoz de la Espada V
An Med Interna; 2005 Nov; 22(11):544-7. PubMed ID: 16454591
[TBL] [Abstract][Full Text] [Related]
6. [Current use of bisphosphonates in clinical oncology].
Vrbanec D; Plestina S; Belev B; Unusić J; Pavlinić-Diminić V
Lijec Vjesn; 1999; 121(9-10):296-301. PubMed ID: 19658372
[TBL] [Abstract][Full Text] [Related]
7. Renal tolerability of intermittent intravenous ibandronate treatment for patients with postmenopausal osteoporosis: a review.
Miller PD; Ward P; Pfister T; Leigh C; Body JJ
Clin Exp Rheumatol; 2008; 26(6):1125-33. PubMed ID: 19210886
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of oral ibandronate versus IV zoledronic acid or IV pamidronate for bone metastases in patients receiving oral hormonal therapy for breast cancer in the United Kingdom.
De Cock E; Hutton J; Canney P; Body JJ; Barrett-Lee P; Neary MP; Lewis G
Clin Ther; 2005 Aug; 27(8):1295-310. PubMed ID: 16199254
[TBL] [Abstract][Full Text] [Related]
9. Bisphosphonates--role in cancer therapies.
Mehrotra B
J Oral Maxillofac Surg; 2009 May; 67(5 Suppl):19-26. PubMed ID: 19371811
[No Abstract] [Full Text] [Related]
10. Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates.
Kimmel DB
J Dent Res; 2007 Nov; 86(11):1022-33. PubMed ID: 17959891
[TBL] [Abstract][Full Text] [Related]
11. [Therapeutic agents for disorders of bone and calcium metabolism: Zoledronic acid].
Sakurai T
Clin Calcium; 2007 Jan; 17(1):24-8. PubMed ID: 17211090
[TBL] [Abstract][Full Text] [Related]
12. Use of bisphosphonates in orthopedic surgery: pearls and pitfalls.
Lozano-Calderon SA; Colman MW; Raskin KA; Hornicek FJ; Gebhardt M
Orthop Clin North Am; 2014 Jul; 45(3):403-16. PubMed ID: 24975766
[TBL] [Abstract][Full Text] [Related]
13. Bisphosphonates in the prevention and treatment of bone metastases.
Ramaswamy B; Shapiro CL
Oncology (Williston Park); 2003 Sep; 17(9):1261-70; discussion 1270-2, 1277-8, 1280. PubMed ID: 14569853
[TBL] [Abstract][Full Text] [Related]
14. [The role of ibandronate in the daily oncological practice].
Nagykálnai T
Magy Onkol; 2006; 50(4):325-7. PubMed ID: 17216006
[TBL] [Abstract][Full Text] [Related]
15. Role of bisphosphonates in prevention and treatment of bone metastases from breast cancer.
Paterson AH; Kanis JA; Powles TJ; McCloskey E; Hanson J; Ashley S
Can J Oncol; 1995 Dec; 5 Suppl 1():54-7. PubMed ID: 8853526
[TBL] [Abstract][Full Text] [Related]
16. Ibandronate: efficacy in the treatment of metastatic bone disease.
Diel IJ
Future Oncol; 2005 Oct; 1(5):593-607. PubMed ID: 16556036
[TBL] [Abstract][Full Text] [Related]
17. Clinical value of bisphosphonates in cancer therapy.
Lüftner D; Henschke P; Possinger K
Anticancer Res; 2007; 27(4A):1759-68. PubMed ID: 17649770
[TBL] [Abstract][Full Text] [Related]
18. Bisphosphonates for malignancy-related bone disease: current status, future developments.
Body JJ
Support Care Cancer; 2006 May; 14(5):408-18. PubMed ID: 16450087
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of the new bisphosphonate ibandronate in the management of bone metastasis following rapid infusion.
Syrigos KN; Michalaki V; Mitromaras A; Pliarchopoulou F; Katirtzoglou N; Antonaki E; Roussou P
In Vivo; 2002; 16(5):361-3. PubMed ID: 12494878
[TBL] [Abstract][Full Text] [Related]
20. Preclinical and clinical efficacy of the bisphosphonate ibandronate in cancer treatment.
Bauss F; Bergström B
Curr Clin Pharmacol; 2008 Jan; 3(1):1-10. PubMed ID: 18690873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]